ENZON PHARMACEUTICALS INC Form 8-K/A August 08, 2011
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2011
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(Exact name of registrant as specified in its charter)

Delaware

(State of	other	jurisdiction	of incor	noration)
١	Diate of	Ouici	Julisaicuon	or meor	poranon

		0-12957 (Commission File Number)	22-2372868 (IRS Employer Identification No.)
20 King	sbridge Road		
Piscata	way, New Jersey	08854	
(Addres	s of Principal Exe	cutive Offices)	
Registra	int's telephone nui	mber, including area code (73	2) 980-4500
		t below if the Form 8-K filing f the following provisions:	is intended to simultaneously satisfy the filing obligation of
0	Written commun	ications pursuant to Rule 425	under the Securities Act (16 CFR 230.425)
0	Soliciting materia	al pursuant to Rule 14a-12 und	der the Exchange Act (16 CFR 240.14a-12)
o 240.14d		ent communications pursuant	to Rule 14d-2(b) under the Exchange Act (16 CFR
o 240.13e		ent communications pursuant	to Rule 13e-4(c) under the Exchange Act (16 CFR

Item 5.07 Submission of Matters to a Vote of Security Holders.

In connection with the results of the non-binding advisory vote on the frequency of future advisory votes on the compensation of the named executive officers of Enzon Pharmaceuticals, Inc. (the "Company") at the Company's Annual Meeting of Stockholders held on May 10, 2011 (the "Annual Meeting"), the Board of Directors decided that a non-binding advisory vote to approve the compensation of the named executive officers of the Company will be included annually in the Company's proxy materials until the next vote on frequency, or until the Board of Directors otherwise determines that a different frequency for such advisory votes is in the best interests of the stockholders of the Company.

The results of the Annual Meeting were disclosed by the Company on a Current Report on Form 8-K filed on May 16, 2011 (the "Original Report"). This Current Report on Form 8-K/A amends the Original Report solely for the purpose of disclosing the Company's decision on the frequency of future say-on-pay votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZON PHARMACEUTICALS, INC.

By:/s/ Andrew Rackear Name: Andrew Rackear

Vice President and General Counsel

Title: